Sue Bell

47.1k total citations · 1 hit paper
70 papers, 4.3k citations indexed

About

Sue Bell is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Sue Bell has authored 70 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 28 papers in Hematology and 20 papers in Molecular Biology. Recurrent topics in Sue Bell's work include Multiple Myeloma Research and Treatments (28 papers), Cancer Treatment and Pharmacology (13 papers) and Protein Degradation and Inhibitors (12 papers). Sue Bell is often cited by papers focused on Multiple Myeloma Research and Treatments (28 papers), Cancer Treatment and Pharmacology (13 papers) and Protein Degradation and Inhibitors (12 papers). Sue Bell collaborates with scholars based in United Kingdom, United States and Australia. Sue Bell's co-authors include Gareth J. Morgan, Faith E. Davies, Mark T. Drayson, Roger G. Owen, J. A. Child, Julia Brown, Peter J. Selby, Kim Hawkins, Graham Jackson and Walter M. Gregory and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Sue Bell

68 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma

2003 1.3k citations J. A. Child, Gareth J. Morgan et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Sue Bell

Since Specialization

Citations

This map shows the geographic impact of Sue Bell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sue Bell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sue Bell more than expected).

Fields of papers citing papers by Sue Bell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sue Bell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sue Bell. The network helps show where Sue Bell may publish in the future.

Co-authorship network of co-authors of Sue Bell

This figure shows the co-authorship network connecting the top 25 collaborators of Sue Bell. A scholar is included among the top collaborators of Sue Bell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sue Bell. Sue Bell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL. 2025 ·Blood ·Andy C. Rawstron, David Cairns, Nichola Webster, Surita Dalal, (unknown), Ruth de Tute, Anna Hockaday, Sharon Jackson, Sue Bell, (unknown), David Stones, David Allsup, Adrian Bloor, Anita Sarma, Abraham Varghese, Talha Munir, Peter Hillmen	0
2	Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patients 2025 ·Blood ·(unknown), Surita Dalal, Darren Newton, (unknown), Nichola Webster, Andy C. Rawstron, Ruth de Tute, Anna Hockaday, Sharon Jackson, Sue Bell, (unknown), David Stones, David Allsup, Adrian Bloor, Anita Sarma, (unknown), Peter Hillmen, (unknown)	0
3	Multicentre Investigation of Prognostic Factors Incorporating p16 and Tumour Infiltrating Lymphocytes for Anal Cancer After Chemoradiotherapy 2021 ·Clinical Oncology ·Katie Wakeham, Louise Murray, R. Muirhead, M. Hawkins, David Sebag‐Montefiore, Sarah Brown, Laura Murphy, Gareth J. Thomas, Sue Bell, (unknown), (unknown), (unknown), Duncan C. Gilbert	8
4	Are we over-treating with checkpoint inhibitors? 2019 ·British Journal of Cancer ·Sarah Danson, Jane Hook, Helen Marshall, (unknown), Sue Bell, (unknown), Pippa Corrie	13
5	P2.16-16 SABRTOOTH: A Fasibility Study of SABR Versus Surgery in Patients with Peripheral Stage I NSCLC Considered to be at Higher Risk for Surgery 2018 ·Journal of Thoracic Oncology ·K. Franks, Lucy McParland, (unknown), David Baldwin, David Sebag‐Montefiore, Matthew Evison, Richard Booton, Corinne Faivre‐Finn, Babu Naidu, (unknown), C. Peedell, (unknown), Martyn Kennedy, Walter M. Gregory, Jenny Hewison, Janine Bestall, Sue Bell, Peter Hall, M. Snee	1
6	Towards a biological monitoring guidance value for acrylamide 2015 ·Toxicology Letters ·Craig Sams, Kate Jones, Nicholas Warren, John Cocker, Sue Bell, Paulina Bull, (unknown)	15
7	Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results. 2012 ·Journal of Clinical Oncology ·Gareth J. Morgan, Graham Jackson, Faith E. Davies, Ping Wu, Walter M. Gregory, Sue Bell, Alexander J. Szubert, Nuria Navarro Coy, Mark T. Drayson, Roger G. Owen, Sylvia Feyler, John Ashcroft, Fiona Ross, Jennifer A. Byrne, Huw Roddie, Claudius Rudin, Kevin Boyd, Gordon Cook, J. Anthony Child	1
8	A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial 2011 ·Leukemia ·Kevin Boyd, F. M. Ross, Laura Chiecchio, Gian Paolo Dagrada, Zoë J. Konn, William Tapper, Brian A. Walker, Christopher P. Wardell, Walter M. Gregory, Alexander J. Szubert, Sue Bell, J. Anthony Child, Graham Jackson, Faith E. Davies, Gareth J. Morgan, (unknown)	224
9	Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial 2011 ·The Lancet Oncology ·Gareth J. Morgan, J. Anthony Child, Walter M. Gregory, Alex J. Szubert, Kim Cocks, Sue Bell, Nuria Navarro-Coy, Mark T. Drayson, Roger G. Owen, Sylvia Feyler, A. John Ashcroft, Fiona M. Ross, Jenny Byrne, Huw Roddie, Claudius Rudin, Gordon Cook, Graham Jackson, Ping Wu, Faith E. Davies	117
10	Nurses' Comfort Level With Emergency Interventions in the Rural Hospital Setting 2009 ·The Journal of Rural Health ·(unknown), Sue Bell	7
11	Genotypic Analysis of Hydatidiform Mole: An Accurate and Practical Method of Diagnosis 2008 ·The American Journal of Surgical Pathology ·Carlo Bifulco, Chaline Johnson, Liming Hao, (unknown), Sue Bell, Pei Hui	64
12	The State Cancer Profiles web site and extensions of linked micromap plots and conditioned choropleth map plots 2003 ·International Conference on Digital Government Research ·Daniel B. Carr, Sue Bell, Linda W. Pickle, (unknown), (unknown)	5
13	High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma breakdown → 2003 ·New England Journal of Medicine ·J. A. Child, Gareth J. Morgan, Faith E. Davies, Roger G. Owen, Sue Bell, Kim Hawkins, Julia Brown, Mark T. Drayson, Peter J. Selby	1348
14	Engaging clinicians with a cancer registry improves ascertainment rates in haematological malignancies. 2002 ·Blood ·Karen Phekoo, Henrik Møller, David Bevan, Sue Bell, Steve Schey	1
15	Immunological and inflammatory characterisation of three canine cell lines: K1, K6 and DH82 2000 ·Veterinary Immunology and Immunopathology ·A. Barnes, (unknown), Sue Bell, (unknown), (unknown), Richard Morris, Stuart Carter	27
16	Predictors of long-term outcome in 45 men with antisocial personality disorder. 1997 ·Annals of Clinical Psychiatry ·Donald W. Black, Patrick O. Monahan, (unknown), Sue Bell	13
17	A 16- to 45-year follow-up of 71 men with antisocial personality disorder 1995 ·Comprehensive Psychiatry ·Donald W. Black, (unknown), Sue Bell	83
18	Screening Infants For Neuroblastoma: The Parents' Perspective 1994 ·Pediatric Hematology and Oncology ·Sue Bell, Louise Parker, Michael Cole, Alan Craft	6
19	Depression and other mental disorders in the relatives of morbidly obese patients 1992 ·Journal of Affective Disorders ·Donald W. Black, Risë B. Goldstein, Edward E. Mason, Sue Bell, (unknown)	26
20	Screening babies for neuroblastoma. 1991 ·PubMed ·Sue Bell	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact